期刊文献+

奥沙利铂对糖尿病与否的胃肠肿瘤神经毒性影响的观察 被引量:1

Effect of Oxaliplatin on Neurotoxicity of Gastrointestinal Tumors with Diabetes Mellitus
暂未订购
导出
摘要 目的观察奥沙利铂化疗对胃肠肿瘤合并糖尿病患者(试验组)与无糖尿病胃肠肿瘤患者(对照组)神经毒性的影响。方法选取60例病理确诊的胃肠肿瘤患者,依据是否合并糖尿病将其列入试验组与对照组,每组各30例。两组患者均使用奥沙利铂进行化疗,观察两组患者神经毒性的发生情况。将试验组根据糖尿病病程分为糖尿病病程>5年组及糖尿病病程≤5年组,比较两组神经毒性反应的发生情况。结果试验组与对照组相比,神经毒性反应发生率为93.3%vs 70.0%,神经毒性的发生时间为(7.8±2.6)周vs (10.3±2.6)周,出现神经毒性时奥沙利铂的累积使用剂量为(563±175)mg vs (746±185)mg,差异有统计学意义(P<0.05)。将试验组根据糖尿病病程分为糖尿病病程>5年组及糖尿病病程≤5年组,结果显示,糖尿病病程>5年组与糖尿病病程≤5年组相比,神经毒性的发生时间为(6±2)周vs(9.5±1.6)周,出现神经毒性时奥沙利铂的累积使用剂量为(440±141)mg vs (685±107)mg,差异有统计学意义(P<0.05)。结论使用奥沙利铂化疗,存在糖尿病合并症的胃肠肿瘤患者神经毒性的发生率更高,发生时间更早,奥沙利铂的累积使用剂量更少。糖尿病病程越长,神经毒性的发生时间更早、奥沙利铂的累积使用剂量更少,要及早的防治。 Objective To observe the effect of oxaliplatin chemotherapy on neurotoxicity in patients with gastrointestinal neoplasms(test group) and patients without diabetes mellitus(control group). Methods 60 patients with pathologically confirmed gastrointestinal tumors were enrolled. According to whether they had diabetes, they were included in the experimental group and the control group, 30 cases in each group. Oxaliplatin was used for chemotherapy in both groups to observe the occurrence of neurotoxicity in the two groups. The experimental group was divided into two groups according to the course of diabetes: the course of diabetes>5 years and the course of diabetes ≤5 years. The incidence of neurotoxicity was compared between the two groups. Results Compared with the control group, the incidence of neurotoxicity was 93.3% vs 70.0%, and the time of neurotoxicity was(7.8±2.6)weeks vs(10.3±2.6)weeks. The accumulation of oxaliplatin in the presence of neurotoxicity dose was(563±175)mg vs(746±185)mg, the difference was statistically significant(P<0.05). According to the course of diabetes, the experimental group was divided into the diabetic course >5 years group and the diabetes course ≤5 years group. The results showed that the duration of neurotoxicity was(6±2)weeks vs(9.5±1.6)weeks compared with the diabetic disease course ≤5 years group, the cumulative dose of oxaliplatin was(440±141)mg vs(685±107)mg when neurotoxicity occurred, and the difference was statistically significant(P<0.05). Conclusion With oxaliplatin chemotherapy, patients with gastrointestinal tumors with diabetes mellitus have a higher incidence of neurotoxicity, occurring earlier, and oxaliplatin has a lower cumulative dose. The longer the course of diabetes, the earlier the occurrence of neurotoxicity, the less cumulative dose of oxaliplatin, and the early prevention and treatment is nessary.
作者 陈程 丁群 CHEN Cheng;DING Qun(Department of Radiation Oncology, Lianyungang Second People's Hospital, Lianyungang, Jiangsu Province, 222023 China;Department of Endocrinology, Lianyungang Second People's Hospital, Lianyungang, Jiangsu Province, 222023 China)
出处 《糖尿病新世界》 2019年第5期101-104,共4页 Diabetes New World Magazine
关键词 胃肠肿瘤 糖尿病 奥沙利铂 化疗 神经毒性 Gastrointestinal neoplasms Diabetes Oxaliplatin Chemotherapy Neurotoxicity
  • 相关文献

参考文献7

二级参考文献79

  • 1杨涛,吴宗群,解建国.抗肿瘤紫杉醇的实验与临床应用进展[J].大连医科大学学报,2007,29(2):197-199. 被引量:9
  • 2King H,Aubert RE,Herman WH.Global burden of diabetes,1995-2025:prevalence,numerical estimates,and projections.Diabetes Care,1998,21:1414-1431.
  • 3Stovring H,Andersen M,Beck-Nielsen H,et al.Rising prevalence of diabetes:evidence from a Danish pharmacy-epidemiolngical database.Lancet,2003,362:537-538.
  • 4Silverman DT,Schiffman M,Everhart J,et al.Diabetes mellitus,other medical conditions and familial history of cancer as risk factors for pancreatic cancer.Br J Cancer,1999,80:1830-1837.
  • 5Yang YX,Hennessy S,Lewis JD.Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.Gastroenterology,2004,127:1044-1050.
  • 6Bayram A,Eksi F,Mehli M.Prevalence of hepatitis E virus antibodies in patients with chronic hepatitis B and chronic hepatitis C.Gastroenterology,2008,134:95-101.
  • 7Larsson SC,Mantzoros CS,Wolk A.Diabetes mellitus and risk of breast cancer:a meta-analysis.Int J Cancer,2007,121:856-862.
  • 8Yancik R,Wesley MN,Ries LA,et al.Effect of age and comorbidity in postmenopansal breast cancer patients aged 55 years and older.JAMA,2001,285:885-892.
  • 9Yancik R,Wesley MN,Ries LA,et al.Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients:a population-based study.Cancer,1998,82:2123-2134.
  • 10Meyerhardt JA,Catalano PJ,Haller DG,et al.Impact of diabetes mellitus on outcomes in patients with colon cancer.J Clin Oncol,2003,21:433-440.

共引文献115

同被引文献19

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部